BCL2 and diffuse large B-cell lymphoma: This molecular profile, characterized by MYC amplification rather than rearrangement in the presence of an IGH::BCL2 fusion, suggests that a tailored treatment regimen, distinct from that used for HGBCL with concurrent MYC and BCL2 rearrangements, may be necessary to optimize clinical outcomes in DLBCL [32,33,34,35,36].